Диссертация (1145849), страница 22
Текст из файла (страница 22)
– V. 76. – №. 3. – P. 225-230.54. Caplan A.I. Mesenchymal stem cells //Journal of orthopaedic research. – 1991. –V. 9. – №. 5. – P. 641-650.55. Cappellesso-Fleury S., Puissant-Lubrano B., Apoil P.A., Titeux M., WintertonP., Casteilla L., Bourin P., Blancher A. Human fibroblasts shareimmunosuppressive properties with bone marrow mesenchymal stem cells//Journal of clinical immunology. – 2010.
– V. 30. – №. 4. – P. 607-619.56. Carvalho M., Teixeira F.G., Reis R.L., Sousa N., Salgado A.J. Mesenchymalstem cells in the umbilical cord: phenotypic characterization, secretome andapplications in central nervous system regenerative medicine //Current stem cellresearch & therapy. – 2011. – V. 6.
– №. 3. – P. 221-228.57. Casiraghi F., Azzollini N., Cassis P., Imberti B., Morigi M., Cugini D., CavinatoR.A., Todeschini M., Solini S., Sonzogni A., Perico N., Remuzzi G., Noris M.Pretransplant infusion of mesenchymal stem cells prolongs the survival of asemiallogeneic heart transplant through the generation of regulatory T cells//The Journal of Immunology.
– 2008. – V. 181. – №. 6. – P. 3933-3946.58. Castonguay R., Werner E.D., Matthews R.G., Presman E., MulivorA.W., Solban N., Sako D., Pearsall R.S., Underwood K.W., Seehra J., Kumar134R., Grinberg A.V. Soluble endoglin specifically binds bone morphogeneticproteins 9 and 10 via its orphan domain, inhibits blood vessel formation, andsuppresses tumor growth //Journal of Biological Chemistry. – 2011.
– V. 286. –№. 34. – P. 30034-30046.59. Cazac B.B., Roes J. TGF-β receptor controls B cell responsiveness andinduction of IgA in vivo //Immunity. – 2000. – V. 13. – №. 4. – P. 443-451.60. Che N., Li X., Zhou S., Liu R., Shi D., Lu L., Sun L. Umbilical cordmesenchymal stem cells suppress B-cell proliferation and differentiation//Cellular immunology. – 2012. – V. 274. – №. 1. – P. 46-53.61. Chen F.E., Huang D.B., Chen Y.Q., Ghosh G. Crystal structure of p50/p65heterodimer of transcription factor NF-κB bound to DNA //Nature.
– 1998. – V.391. – №. 6665. – P. 410-413.62. Chen D., Ma F., Xu S., Yang S., Chen F., Rong L., Chi Y., Zhao Q., Lu S., HanZ., Pang A., Han Z. Expression and role of Toll-like receptors on humanumbilical cord mesenchymal stromal cells //Cytotherapy. – 2013.
– V. 15. – №.4. – P. 423-433.63. Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J., Letarte M.Endoglin is a component of the transforming growth factor-beta receptor systemin human endothelial cells //Journal of Biological Chemistry.
– 1992. – V. 267.– №. 27. – P. 19027-19030.64. Cho K.S., Park M.K., Kang S.A., Park H.Y., Hong S.L., Park H.K., Yu H.S.,Roh H.J. Adipose-Derived Stem Cells Ameliorate Allergic AirwayInflammation by Inducing Regulatory T Cells in a Mouse Model of Asthma//Mediators of inflammation.
– 2014. – V. 2014.65. Conconi M.T., Di Liddo R., Tommasini M., Calore C., Parnigotto P.P.Phenotype and differentiation potential of stromal populations obtained fromvarious zones of human umbilical cord: an overview // The Open Tissue EngRegen Med J. – 2011. – V. 4.
– P. 6-20.66. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., CazzantiF., Risso M., Gualandi F., Mancardi G.L., Pistoia V., Uccelli A. Humanmesenchymal stem cells modulate B-cell functions //Blood. – 2006. – V. 107. –№. 1. – P. 367-372.67. Corrigan C.J., Kay A.B. CD4 T-lymphocyte activation in acute severe asthma:relationship to disease severity and atopic status //American Review ofRespiratory Disease. – 1990. – V. 141. – №. 4. – P. 970-977.68. Corthay A. How do regulatory T cells work? //Scandinavian journal ofimmunology. – 2009.
– V. 70. – №. 4. – P. 326-33613569. Covas D.T., Panepucci R.A., Fontes A.M., Silva W.A. Jr, Orellana M.D., FreitasM.C., Neder L., Santos A.R., Peres L.C., Jamur M.C., Zago M.A. Multipotentmesenchymal stromal cells obtained from diverse human tissues sharefunctional properties and gene-expression profile with CD146+ perivascularcells and fibroblasts //Experimental hematology.
– 2008. – V. 36. – №. 5. – P.642-654.70. Covert M.W., Leung T.H., Gaston J.E., Baltimore D. Achieving stability oflipopolysaccharide-induced NF-κB activation //Science. – 2005. – V. 309. – №.5742. – P. 1854-1857.71. Craig W., Kay R., Cutler R.L., Lansdorp P.M. Expression of Thy-1 on humanhematopoietic progenitor cells //The Journal of experimental medicine. – 1993.– V. 177. – №. 5. – P.
1331-1342.72. Crisan M., Chen C.W., Corselli M., Andriolo G., Lazzari L., Péault B.Perivascular multipotent progenitor cells in human organs //Annals of the NewYork Academy of Sciences. – 2009. – V. 1176. – №. 1. – P. 118-123.73. Crop M.J., Baan C.C., Korevaar S.S., Ijzermans J.N., Pescatori M., Stubbs A.P.,van Ijcken W.F., Dahlke M.H., Eggenhofer E., Weimar W., Hoogduijn M.J.Inflammatory conditions affect gene expression and function of human adiposetissue-derived mesenchymal stem cells //Clinical & Experimental Immunology.– 2010.
– V. 162. – №. 3. – P. 474-486.74. D’Ambrosio D., Trotta R., Vacca A., Frati L., Santoni A., Gulino A., Testi R.Transcriptional regulation of interleukin-2 gene expression by CD69-generatedsignals //European journal of immunology.
– 1993. – V. 23. – №. 11. – P. 29932997.75. Das M., Bouchey D.M., Moore M.J., Hopkins D.C., Nemenoff R.A., StenmarkK.R. Hypoxia-induced proliferative response of vascular adventitial fibroblastsis dependent on G protein-mediated activation of mitogen-activated proteinkinases //Journal of Biological Chemistry. – 2001. – V.
276. – №. 19. – P.15631-15640.76. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potentialclinical uses //Experimental hematology. – 2000. – V. 28. – №. 8. – P. 875-884.77. DelaRosa O., Dalemans W., Lombardo E. Toll-like receptors as modulators ofmesenchymal stem cells //Frontiers in immunology. – 2012. – V. 3.78. ten Dijke P., Goumans M.J., Pardali E. Endoglin in angiogenesis and vasculardiseases //Angiogenesis. – 2008. – V. 11.
– №. 1. – P. 79-89.79. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., MatteucciP., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T136lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli//Blood. – 2002. – V. 99. – №. 10. – P. 3838-3843.80. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., KrauseD., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for definingmultipotent mesenchymal stromal cells. The International Society for CellularTherapy position statement //Cytotherapy.
– 2006. – V. 8. – №. 4. – P. 315-317.81. Dorronsoro A., Ferrin I., Salcedo J.M., Jakobsson E., Fernández-Rueda J., LangV., Sepulveda P., Fechter K., Pennington D., Trigueros C. Human mesenchymalstromal cells modulate T-cell responses through TNFα-mediated activation ofNF-κB //European journal of immunology. – 2014. – V. 44. – №. 2. – P.
480488.82. Duffy M.M., Ritter T., Ceredig R., Griffin M.D. Mesenchymal stem cell effectson T-cell effector pathways //Stem Cell Res Ther. – 2011. – V. 2. – №. 4. – P.34.83. Ebert E.C., Mehta V., Das K.M. Activation antigens on colonic T cells ininflammatory bowel disease: effects of IL-10 //Clinical & ExperimentalImmunology. – 2005. – V. 140. – №.
1. – P. 157-165.84. Eliasson P., Jönsson J.I. The hematopoietic stem cell niche: low in oxygen but anice place to be //Journal of cellular physiology. – 2010. – V. 222. – №. 1. – P.17-2285. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFNγ and TNF-αdifferentially regulate immunomodulation by murine mesenchymal stem cells//Immunology letters. – 2007. – V. 110. – №. 2. – P. 91-100.86. English K., Ryan J.M., Tobin L., Murphy M.J., Barry F.P., Mahon B.P.
Cellcontact, prostaglandin E2 and transforming growth factor beta 1 play nonredundant roles in human mesenchymal stem cell induction of CD4+ CD25Highforkhead box P3+ regulatory T cells //Clinical & ExperimentalImmunology. – 2009. – V. 156. – №. 1. – P. 149-160.87. English K.
Mechanisms of mesenchymal stromal cell immunomodulation//Immunology and cell biology. – 2013. – V. 91. – №. 1. – P. 19-26.88. Ennis J., Sarugaser R., Gomez A., Baksh D., Davies J.E. Isolation,characterization, and differentiation of human umbilical cord perivascular cells(HUCPVCs) //Methods in cell biology. – 2008. – V. 86.
– P. 121-136.89. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in humanumbilical cord blood //British journal of haematology. – 2000. – V. 109. – №. 1.– P. 235-242.13790. Erdös E.G., Skidgel R.A. Neutral endopeptidase 24.11 (enkephalinase) andrelated regulators of peptide hormones //The FASEB journal. – 1989. – V. 3. –№. 2. – P.
145-151.91. Esplugues E., Sancho D., Vega-Ramos J., Martínez C., Syrbe U., HamannA., Engel P., Sánchez-Madrid F., Lauzurica P. Enhanced antitumor immunity inmice deficient in CD69 //The Journal of experimental medicine. – 2003. – V.197. – №. 9. – P. 1093-1106.92. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A. Natural killercell receptors: new biology and insights into the graft-versus-leukemia effect//Blood. – 2002.
– V. 100. – №. 6. – P. 1935-1947.93. Farias V.A., Linares-Fernández J.L., Peñalver J.L., Payá Colmenero .JA., FerrónG.O., Duran E.L., Fernández R.M., Olivares E.G., O'Valle F., Puertas A., OliverF.J., Ruiz de Almodóvar J.M. Human umbilical cord stromal stem cell expressCD10 and exert contractile properties //Placenta. – 2011. – V. 32. – №. 1.
– P.86-95.94. Fehrer C., Brunauer R., Laschober G., Unterluggauer H., Reitinger S., Kloss F.,Gülly C., Gassner R., Lepperdinger G. Reduced oxygen tension attenuatesdifferentiation capacity of human mesenchymal stem cells and prolongs theirlifespan //Aging cell. – 2007.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
